Psychiatr Prax 2014; 41(01): 55-56
© Georg Thieme Verlag KG Stuttgart · New York Mitteilungen des Arbeitskreises der Chefärzte und Chefärztinnen von Kliniken für Psychiatrie
und Psychotherapie an Allgemeinkrankenhäusern in Deutschland (ACKPA)
Karl H. Beine
Hamm
› Author Affiliations
Literatur
1 Gunnell D, Saperia J, Ashby D. Selective serotonin reuptake inhibitors (SSRIs) and
suicide in adults: meta-analysis of drug company data from placebo controlled, randomised
controlled trials submitted to the MHRA’s safety review. BMJ 2005; 330: 385-389 2 Hammad TA, Laughren TP, Racoosin JA. Suicide rates in short-term randomized controlled
trials of newer antidepressants. J Clin Psychopharmacol 2006; 26: 203-207 3 Khan A, Khan S, Kolts R et al. Suicide rates in clinical trials of SSRIs, other antidepressants,
and placebo: analysis of FDA reports. Am J Psychiatry 2003; 160: 790-792 4 Khan A, Khan SR, Leventhal RM et al. Symptom reduction and suicide risk in patients
treated with placebo in antidepressant clinical trials: a replication analysis of
the Food and Drug Administration Database. Int J Neuropsychopharmacol 2001; 4: 113-118
5 Khan A, Warner HA, Brown WA. Symptom reduction and suicide risk in patients treated
with placebo in antidepressant clinical trials: an analysis of the Food and Drug Administration
database. Arch Gen Psychiatry 2000; 57: 311-317 6 Fergusson D, Doucette S, Glass KC et al. Association between suicide attempts and
selective serotonin reuptake inhibitors: systematic review of randomised controlled
trials. BMJ 2005; 330: 396-402 7 Storosum JG, van Zwieten BJ, van den Brink W et al. Suicide risk in placebo-controlled
studies of major depression. Am J Psychiatry 2001; 158: 1271-1275 8 Gibbons RD, Hur K, Brown CH et al. Benefits from antidepressants synthesis of 6-week
patient-level outcomes from double-blind placebo-controlled randomized trials of fluoxetine
and venlafaxine. Arch Gen Psychiatry 2012; 69: 572-579 9 Gibbons RD, Brown CH, Hur K et al. Suicidal thoughts and behavior with antidepressant
treatment reanalysis of the ran-domized placebo-controlled studies of fluoxetine and
venlafaxine. Arch Gen Psychiatry 2012; 69: 580-587 10 Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960; 23:
56-62 11 DGPPN, BÄK, KBV, AWMF, AkdÄ, BPtK, BApK, DAGSHG, DEGAM, DGPM, DGPs, DGRW (Hrsg) für
die Leitliniengruppe Unipolare Depression. S3-Leitlinie/Nationale Versorgungs-Leitlinie
Unipolare Depression. 1.. Auflage Berlin, Düsseldorf: DGPPN, ÄZQ, AWMF; 2009. Internet:
www.dgppn.de www.versorgungsleitlinien.de www.awmf-leitlinien.de
